Tech Announces Availability News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DGAP-News: AIM I ... DGAP-News: AIM ImmunoTech Inc: AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers vom 24.12.2020, 14:15 Uhr Bild: pixabay.com DGAP-News: AIM ImmunoTech Inc / Key word(s): Miscellaneous AIM ImmunoTech Inc: AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers 24.12.2020 / 14:15 The issuer is solely responsible for the content of this announcement. AIM ImmunoTech Announces that the ME/CFS Clinical Trial of its Drug...

AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 'Long Haulers' Institutional Review Board Authorizes Public Notification for Potential

| Press Release AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers' Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects OCALA, FL / ACCESSWIRE / December 24, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) announced today that the post-COVID-19 "Long Hauler" portion of the active AMP-511 Expanded Access Program (EAP) protocol received approval fr...